分子影像SPECT/CT对乳腺癌骨转移的临床应用价值  

The clinical application value of molecular imaging SPECT/CT for bone metastases from breast cancer

作　　者：董科[1] 傅健飞[2] 楼菁菁 刘江[1] 傅健飞 

机构地区：[1]金华市中心医院核医学科,浙江金华321000 [2]金华市中心医院核医学科,321000

出　　处：《中国临床医学影像杂志》2015年第7期465-468,共4页Journal of China Clinic Medical Imaging

摘　　要：目的:探讨分子影像SPECT/CT对乳腺癌骨转移的临床应用价值。方法 :回顾性分析多层螺旋CT与SPECT/CT融合显像对68个疑似乳腺癌骨转移病灶的检查结果,进行统计学检验。结果:经临床确诊乳腺癌骨转移的55个病灶中:MSCT诊断的敏感度为78.2%(43/55),特异性为92.3%(12/13),准确性为80.9%(55/68);SPECT/CT融合显像诊断敏感度为96.4%(53/55),特异性为76.9%(10/13),准确性为92.6%(63/68)。2种检查方法的敏感度、准确性差异有统计学意义(P<0.05),特异性差异无统计意义。结论:SPECT/CT融合显像相对于MSCT检查,可提高对乳腺癌骨转移的诊断敏感性和准确性,具有较好的临床应用价值。Objective： To investigate the clinical application value of the molecular imaging SPECT/CT for bone metastases of breast cancer. Methods： Both MSCT and SPECT/CT imaging data of 68 suspicious bone metastases lesions of breast cancer were retrospectively analyzed and compared, and the statistics checkout was carried out. Resluts： Among the 55 bone metas- tases lesions of breast cancer, sensitivity, specificity and accuracy of bone metastases diagnosed by MSCT were 78.2%（43/55）, 92.3%（12/13） and 80.9%（55/68）; and sensitivity, specificity and accuracy of bone metastases diagnosed by SPECT/CT were 96.4%（53/55）, 76.9%（10/13） and 92.6%（63/68）. For the difference of the sensitivity and accuracy, there was statistically signifi- cance between MSCT and SPECT methods（P〈0.05）, and the specificity of both methods was no difference. Conclusions： Com- paring with MSCT, the SPECT/CT fusion imaging can improve the sensitivity and accuracy of the bone metastases diagnosis of breast cancer, and having better clinical application value.

关 键 词：乳腺肿瘤 肿瘤转移 体层摄影术 发射型计算机 单光子 

分 类 号：R737.9[医药卫生—肿瘤] R814.42[医药卫生—临床医学]